Fat Loss Research Stack

Fat Loss Stack – Retatrutide + 5‑Amino‑1MQ Metabolic Blend

The Fat Loss Stack combines Retatrutide, a next‑generation triple incretin agonist candidate, with 5‑Amino‑1MQ, a small‑molecule NNMT inhibitor, to enable multi‑angle exploration of fat‑loss biology. Retatrutide acts at the level of gut‑hormone signaling and energy balance, while 5‑Amino‑1MQ targets intracellular nicotinamide N‑methyltransferase (NNMT) and NAD⁺‑linked metabolism, giving researchers a coordinated way to study both systemic and cellular drivers of adiposity.

Key components and conceptual roles

• Retatrutide – Triple incretin and energy‑balance axis
  An investigational peptide agonist of GIP, GLP‑1, and glucagon receptors, useful in models focused on appetite, gastric emptying, insulin and glucagon dynamics, and energy expenditure. It anchors the stack’s hormonal and whole‑body weight‑regulation arm, especially in diet‑induced obesity or insulin‑resistance paradigms.

• 5‑Amino‑1MQ – NNMT and NAD⁺‑linked metabolism
  A membrane‑permeable small molecule that inhibits NNMT, a key enzyme involved in nicotinamide methylation and NAD⁺ availability. It is used to explore changes in adipocyte size, fat storage, resting energy expenditure, and muscle performance in models where intracellular energy handling and adipose biology are central.

Together, these agents allow investigators to examine how reshaping incretin signaling and NNMT/NAD⁺ metabolism in parallel might influence weight, fat distribution, and metabolic health markers more than either approach alone.

Research applications

This Fat Loss Stack is suited for experimental systems investigating:

• Diet‑induced obesity and metabolic syndrome, including endpoints such as body‑weight trajectory, fat‑mass vs lean‑mass changes, glucose/insulin curves, and lipid panels.

• Adipocyte biology and adipose‑tissue remodeling, tracking adipocyte size, tissue histology, inflammatory markers, and gene expression related to lipolysis and lipogenesis.

• Energy‑expenditure and performance‑adjacent models, examining resting metabolic rate, substrate utilization (RQ), endurance, and muscle function under altered incretin and NNMT signaling.

• Early‑stage cardiometabolic risk research, where weight, visceral adiposity, and insulin sensitivity are studied as upstream drivers of downstream cardiovascular endpoints.

Recommended handling

• For controlled laboratory research use only, by qualified professionals.

• Store each component (Retatrutide and 5‑Amino‑1MQ) in a cool, dry environment away from light, and follow your institution’s SOPs for storage, reconstitution (for peptide), aliquoting, and disposal.

• Investigators should design dose‑escalation schemes, timing relative to feeding, and outcome measures based on the individual literature for each compound and the specific obesity/metabolic model being used.

Important disclaimer

All compounds sold by Rocky Peptide Chain, including the Fat Loss Stack (Retatrutide and 5‑Amino‑1MQ), are for research use only. They are not intended for human consumption, medical use, diagnostic purposes, or treatment of any disease or condition. No claims are made or implied regarding weight loss, body‑recomposition, blood‑sugar control, or therapeutic benefit. Researchers are solely responsible for appropriate handling, experimental design, and compliance with all applicable regulations.